Radient Announces Brokered Private Placement for Proceeds of $6 Million

Aurora Cannabis to Participate as Lead Investor

VANCOUVER, Feb. 13, 2017 /CNW/ - Radient Technologies ("Radient") (TSX-V: RTI) is pleased to announce a brokered private placement for up to $6 million, with Aurora Cannabis ("Aurora") (TSX-V: ACB) participating as a lead investor.

Radient  has entered into an agreement with Canaccord Genuity Corp. (the "Agent") with respect to a brokered private placement of up to 13,333,333 units (the "Units") at $0.45 per unit for aggregate proceeds of up to $6 million (the "Offering") to be conducted on a commercially reasonable efforts basis, subject to satisfactory due diligence. The Agent has also been granted the option (the "Over-Allotment Option") to purchase up to an additional 15% of the number of Units issuable under the Offering.

Aurora has advised Radient that it intends to participate in the Offering in an amount up to $1.25 million, approximately 22% of the total proceeds.

The proceeds of the Offering will be used for the acquisition of analytical and production equipment, improvements to the plant to accommodate cannabinoid production and general working capital.

Each Unit is comprised of one common share of Radient (a "Common Share") and one half Common Share purchase warrant (each whole warrant, a "Unit Warrant"), with each whole Unit Warrant entitling the holder to subscribe for one additional Common Share at a price of $0.70 per Common Share until the date that is 24 months from the date of issuance. 

As compensation for its services, Radient will issue to the Agent that number of non-transferable common share purchase warrants ("Broker Warrants") equal to 7% of the total number of Units sold under the Offering (including any Units issued upon exercise of the Over-Allotment Option), other than in respect of orders from "president's list" purchasers on which the Agent will receive Broker Warrants equal to 3.5% of the Units sold.  Each Broker Warrant will entitle the Agent to acquire one Unit at an exercise price of $0.45 for a period of 24 months following the completion of the Offering. The Agent will also receive a cash commission of up to 7% of the gross proceeds of the Offering (including in respect of any exercise of the Over-Allotment Option), other than in respect of orders from "president's list", purchasers on which a reduced commission will be paid and will comprise of finders fees in accordance with the policies of the TSX Venture Exchange.

The Offering is subject to the receipt of all necessary approvals, including the final approval of the TSX Venture Exchange. All securities issued in connection with the Offering are subject to a statutory four-month hold period.

About Radient

Radient extracts natural compounds from a range of biological materials using its proprietary MAP^TM natural product extraction technology platform which provides superior customer outcomes in terms of ingredient purity, yield, and cost. From its initial 20,000 square foot manufacturing plant in Edmonton, Alberta, Radient serves market leaders in industries that include pharmaceutical, food, beverage, natural health, personal care and biofuel markets. Visit www.radientinc.com for more information.

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. The forward-looking statements include statements about the the Offering and the use of proceeds thereof.  Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Radient Technologies Inc.

To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/February2017/13/c5598.html